Successful use of secukinumab in pustular psoriasis
نویسندگان
چکیده
BSA: body surface area DLQI: Dermatology Life Quality Index IL-17A: interleukin-17A PASI: Psoriasis Area and Severity Index INTRODUCTION Psoriasis is a common chronic immunologic condition of the skin and nails that affects approximately 2% of the population and is characterized by red elevated plaques with silvery scale. Various forms exist, of which, chronic plaque psoriasis is most common, occurring in 90% of patients. Other less common forms, including guttate, pustular, inverse, and erythrodermic, may appear spontaneously or evolve from plaque psoriasis. Psoriatic arthritis exists in around 20% to 30% of patients suffering from moderate to severe psoriasis. In recent years, the importance of T helper 17 cells and associated pathologic enhanced expression of the cytokine interleukin-17A (IL-17A) were discovered tobe integral to thepathogenesis of psoriasis and psoriatic arthritis. Novel biologic therapies, such as secukinumab and ixekizumab, are monoclonal antibodies that selectively bind to and inhibit IL-17A, whereas brodalumab binds to the IL-17RA receptor. These drugs were found in clinical trials to be highly effective in treating patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Currently, only secukinumab from this class has receivedHealth Canada and US Food and Drug Administration approval for treatment of moderate-to-severe psoriasis, whereas ixekizumab and brodalumab are still under clinical development.* Secukinumab has also
منابع مشابه
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
INTRODUCTION Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustek...
متن کاملSuccessful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
Treatment of von Zumbusch pustular psoriasis is a formidable task, especially when confounded by concomitant human immunodeficiency virus (HIV) infection. To our knowledge, this is the first report of successful use of a biologic agent to treat a patient with both von Zumbusch pustular psoriasis and HIV. Given the propensity of HIV to both trigger and exacerbate psoriasis and the potentially se...
متن کاملSuccessful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection.
Von Zumbusch generalized pustular psoriasis (GPP) is the most severe type of psoriasis with possible life-threatening complications. We report the case of a 22-year-old woman who presented with a severe eruption of generalized pustular psoriasis 48 hours after receiving an injection of etanercept (Enbrel).
متن کاملTreatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
Psoriasis is a chronic inflammatory skin disease that has a negative impact on psychosocial well-being and cardiometabolic health. Treatment options for moderate-to-severe psoriasis have expanded with the development of interleukin-17 (IL-17) inhibitors, the first of which is now available - secukinumab. Secukinumab is a fully human monoclonal immunoglobulin G1 κ antibody that selectively inhib...
متن کامل